Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
August 17, 2022 06:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
August 15, 2022 16:01 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Updates
August 15, 2022 07:02 ET
|
Viridian Therapeutics, Inc
- Positive initial clinical data from ongoing Phase 1/2 Trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED) - - VRDN-002 achieved a substantially extended half-life of 30-40 days in...
Viridian Announces Positive Initial Clinical Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)
August 15, 2022 06:59 ET
|
Viridian Therapeutics, Inc
- Significant and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/kg VRDN-001 - - Proptosis response achieved by 83% of patients with a mean reduction of...
Viridian Therapeutics to Report Second Quarter 2022 Financial Results and Host Conference Call on August 15, 2022
August 08, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 05, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., July 08, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (Nasdaq: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer
June 23, 2022 07:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 03, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., June 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN) (the “Company” or “Viridian”), a biotechnology company advancing new treatments for patients suffering...
Viridian Therapeutics to Participate in June Investor Conferences
June 01, 2022 08:00 ET
|
Viridian Therapeutics, Inc
WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases...